- Home
- PODC vs ARTV Comparison
PODC vs ARTV Comparison
Compare PODC & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- ARTV
- Stock Information
- Founded
- PODC 2013
- ARTV 2019
- Country
- PODC United States
- ARTV United States
- Employees
- PODC N/A
- ARTV N/A
- Industry
- PODC
- ARTV
- Sector
- PODC
- ARTV
- Exchange
- PODC Nasdaq
- ARTV NYSE
- Market Cap
- PODC 44.1M
- ARTV 41.2M
- IPO Year
- PODC N/A
- ARTV 2024
- Fundamental
- Price
- PODC $1.90
- ARTV $3.60
- Analyst Decision
- PODC
- ARTV Strong Buy
- Analyst Count
- PODC 0
- ARTV 8
- Target Price
- PODC N/A
- ARTV $18.14
- AVG Volume (30 Days)
- PODC 105.3K
- ARTV 373.8K
- Earning Date
- PODC 08-12-2025
- ARTV 08-28-2025
- Dividend Yield
- PODC N/A
- ARTV N/A
- EPS Growth
- PODC N/A
- ARTV N/A
- EPS
- PODC N/A
- ARTV N/A
- Revenue
- PODC $52,119,000.00
- ARTV N/A
- Revenue This Year
- PODC $19.39
- ARTV N/A
- Revenue Next Year
- PODC $23.41
- ARTV N/A
- P/E Ratio
- PODC N/A
- ARTV N/A
- Revenue Growth
- PODC 20.36
- ARTV N/A
- 52 Week Low
- PODC $1.10
- ARTV $1.47
- 52 Week High
- PODC $2.94
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- PODC 42.50
- ARTV N/A
- Support Level
- PODC $1.92
- ARTV N/A
- Resistance Level
- PODC $2.06
- ARTV N/A
- Average True Range (ATR)
- PODC 0.21
- ARTV 0.00
- MACD
- PODC -0.04
- ARTV 0.00
- Stochastic Oscillator
- PODC 12.93
- ARTV 0.00
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).